BioAdaptives, Inc. (OTC: BDPT) has detailed the scientific strategy behind its Xcellara cellular wellness platform as it prepares for the Aug. 1 commercial launch of XcellaraHeart, the platform's first targeted application. The platform integrates a stem/progenitor cell mobilization base, supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients designed to support the body's natural signaling pathways and direct those cells to targeted areas, according to a press release.
XcellaraHeart pairs the Xcellara base with Tanshinone IIA, a compound derived from the herb Danshen that has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling. This approach represents what the company calls a "supply-and-direction" model, aiming to both increase the number of circulating stem cells and guide them to specific tissues. The company plans to expand the platform with additional formulas targeting joint mobility, skin health, cognitive wellness, and metabolic resilience using the same development model.
The announcement comes as BioAdaptives prepares to release the complete scientific evidence dossier for XcellaraHeart at products.xcellara.com/science. The dossier will separate findings from the company's human clinical research on the Xcellara base from published research on Tanshinone IIA and the product-development rationale for combining the two. The Xcellara base formula is described as the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters.
BioAdaptives' flagship Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. The company's strategy underscores a growing trend in the nutraceutical industry toward evidence-based formulations that leverage clinical data to support marketing claims. By focusing on cellular mechanisms and targeted delivery, BioAdaptives aims to differentiate its products in a competitive market.
For more information about BioAdaptives and its Xcellara platform, visit www.bioadaptives.com and products.xcellara.com.
